IL-4R presented a decrease in all three stages II, III, and IV in non-tumor adjacent tissue regarding stage I. This decrease could mean that IL-4 cannot alleviate the promotion of inflammation started in non-tumor adjacent tissue because IL-4 has an anti-inflammatory role, as it downregulates NF-κB transactivation induced by proinflammatory cytokines, decreasing IκB proteasome degradation [34]. This evidence concerns the gene NFKB1 and neoplasm.